Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?

Executive Summary

Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.

Advertisement

Related Content

100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year
PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications
PDUFA VI: A Machine To Speed R&D Time, Cut Costs
CDER Pharmaceutical Quality Office Gains Permanent Director
PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections

Topics

Advertisement
UsernamePublicRestriction

Register

PS120348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel